Literature DB >> 24993905

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.

Heidrun Gevensleben1, Verena Bossung, Alfons Meindl, Barbara Wappenschmidt, Nikolaus de Gregorio, Ana Osorio, Atocha Romero, Reinhard Buettner, Birgid Markiefka, Rita Katharina Schmutzler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24993905     DOI： 10.1007/s00428-014-1619-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  6 in total

1.  High nuclear poly(adenosine diphosphate-ribose) polymerase expression is predictive for BRCA1- and BRCA2-deficient breast cancer.

Authors:  Luka Ozretić; Kerstin Rhiem; Sebastian Huss; Barbara Wappenschmidt; Birgid Markiefka; Peter Sinn; Rita K Schmutzler; Reinhard Buettner
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

2.  RAD51C is a susceptibility gene for ovarian cancer.

Authors:  Liisa M Pelttari; Tuomas Heikkinen; Deborah Thompson; Anne Kallioniemi; Johanna Schleutker; Kaija Holli; Carl Blomqvist; Kristiina Aittomäki; Ralf Bützow; Heli Nevanlinna
Journal:  Hum Mol Genet       Date:  2011-05-25       Impact factor: 6.150

3.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

4.  Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.

Authors:  José Palacios; Emiliano Honrado; Ana Osorio; Alicia Cazorla; David Sarrió; Alicia Barroso; Sandra Rodríguez; Juan C Cigudosa; Orland Diez; Carmen Alonso; Enrique Lerma; Lydia Sánchez; Carmen Rivas; Javier Benítez
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

5.  RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families.

Authors:  Gioia Schnurbein; Jan Hauke; Barbara Wappenschmidt; Nana Weber-Lassalle; Stefanie Engert; Heide Hellebrand; Lutz Garbes; Alexandra Becker; Guido Neidhardt; Kerstin Rhiem; Alfons Meindl; Rita K Schmutzler; Eric Hahnen
Journal:  Breast Cancer Res       Date:  2013-12-20       Impact factor: 6.466

6.  Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.

Authors:  J M Cunningham; M S Cicek; N B Larson; J Davila; C Wang; M C Larson; H Song; E M Dicks; P Harrington; M Wick; B J Winterhoff; H Hamidi; G E Konecny; J Chien; M Bibikova; J-B Fan; K R Kalli; N M Lindor; B L Fridley; P P D Pharoah; E L Goode
Journal:  Sci Rep       Date:  2014-02-07       Impact factor: 4.379
  6 in total
  6 in total

1.  Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.

Authors:  Lisa Golmard; Laurent Castéra; Sophie Krieger; Virginie Moncoutier; Khadija Abidallah; Henrique Tenreiro; Anthony Laugé; Julien Tarabeux; Gael A Millot; André Nicolas; Marick Laé; Caroline Abadie; Pascaline Berthet; Florence Polycarpe; Thierry Frébourg; Camille Elan; Antoine de Pauw; Marion Gauthier-Villars; Bruno Buecher; Marc-Henri Stern; Dominique Stoppa-Lyonnet; Dominique Vaur; Claude Houdayer
Journal:  Eur J Hum Genet       Date:  2017-11-08       Impact factor: 4.246

Review 2.  Genotype/Phenotype correlations in patients with hereditary breast cancer.

Authors:  Maike Wittersheim; Reinhard Büttner; Birgid Markiefka
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

3.  Estrogen induces RAD51C expression and localization to sites of DNA damage.

Authors:  Anya Alayev; Rachel S Salamon; Subrata Manna; Naomi S Schwartz; Adi Y Berman; Marina K Holz
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

4.  Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.

Authors:  M Tumiati; P M Munne; H Edgren; S Eldfors; A Hemmes; S G Kuznetsov
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

5.  A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect.

Authors:  Lesa M Dawson; Kerri N Smith; Salem Werdyani; Robyn Ndikumana; Cindy Penney; Louisa L Wiede; Kendra L Smith; Justin A Pater; Andrée MacMillan; Jane Green; Sheila Drover; Terry-Lynn Young; Darren D O'Rielly
Journal:  Mol Genet Genomic Med       Date:  2019-11-28       Impact factor: 2.183

6.  Expression of RAD51 and Its Clinical Impact in Oral Squamous Cell Carcinoma.

Authors:  Yuyang Li; Jia Li; Jingchun Sun; Yingkun Liu; Dingkun Liu; Liuyi Du; Bizhou Wang; Weiwei Liu
Journal:  Anal Cell Pathol (Amst)       Date:  2020-03-03       Impact factor: 2.916
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.